Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 20 (RPL23AP20)
- Target
- RPL23AP20
- Molecular classification
- Other (Pseudogene), Non-coding RNA (since many ribosomal pseudogenes are transcribed as lncRNAs)
01
Overview
RPL23AP20 (ribosomal protein L23a pseudogene 20) is classified as a human pseudogene—a non-functional segment of DNA similar in sequence to the protein-coding ribosomal protein L23a gene (RPL23A). Unlike its functional counterpart, RPL23AP20 does not encode a ribosomal protein and consequently does not participate in protein synthesis or subunit assembly. Ribosomal protein pseudogenes are widely dispersed in the human genome and may, in some cases, produce non-coding RNA transcripts, but for the majority, including RPL23AP20, their biological significance remains unknown or minimal. Pseudogenes are broadly studied for potential regulatory effects on gene expression and, in rarer cases, as non-coding RNA biomarkers, but no direct evidence links RPL23AP20 itself to specific cellular functions, disease mechanisms, or therapeutic applications.
- Other names
- RPL23AP20Ribosomal protein L23a pseudogene 20RPL23A_6_188
02
Mechanism of action
Pseudogenes are generally not targeted by drugs, and RPL23AP20 does not encode a protein.
03
Biological functions
Other: While not protein-coding, some ribosomal protein pseudogenes may function as regulatory non-coding RNAs (lncRNAs) impacting transcription or immune/inflammatory processes in certain contextsRibosomal protein pseudogenes have been linked by analogy to regulation of cell cycle, transcription, metabolism (from RPL23AP53), but no direct evidence exists for RPL23AP20 itself
04
Disease associations
Other. No evidence supports a direct role of RPL23AP20 in any disease. Other ribosomal pseudogenes (like RPL23AP53) have been explored for putative biomarker roles in melanoma, but not RPL23AP20 specifically.
05
Safety considerations
None reported. As a non-functional pseudogene, RPL23AP20 is not associated with any therapeutic safety concern.
06
Interacting drugs
None
07
Biomarkers
None specific to RPL23AP20. Other closely related pseudogenes (e.g., RPL23AP53) are being researched as putative biomarkers in melanoma, but there is no evidence or published biomarker utility for RPL23AP20.
Beyond the preview
Go deeper on Ribosomal protein L23a pseudogene 20 (RPL23AP20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 20 (RPL23AP20).